Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

dc.contributor.author	Ruiz Cobo, J. C.
dc.contributor.author	Llaneras, J.
dc.contributor.author	Forns, X.
dc.contributor.author	Rodríguez García, Manuel
dc.contributor.author	(et al.)
dc.date.accessioned	2024-11-07T07:23:58Z
dc.date.available	2024-11-07T07:23:58Z
dc.date.issued	2024
dc.identifier.citation	Alimentary Pharmacology and Therapeutics (2024); doi:10.1111/apt.18020
dc.identifier.issn	0269-2813
dc.identifier.uri	https://hdl.handle.net/10651/75396
dc.language.iso	eng
dc.relation.ispartof	Alimentary Pharmacology and Therapeutics
dc.rights	© 2024 The Authors
dc.rights	CC Reconocimiento – No Comercial – Sin Obra Derivada 4.0 Internacional
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	Scopus
dc.source.uri	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85192173049&doi=10.1111%2fapt.18020&partnerID=40&md5=0a05df466a2c0ebf04b0a0072ac963bb
dc.title	Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
dc.type	journal article
dc.identifier.doi	10.1111/apt.18020
dc.relation.publisherversion	http://dx.doi.org/10.1111/apt.18020
dc.rights.accessRights	open access

Este ítem está sujeto a una licencia Creative Commons